Cifarelli V, Hursting S D
Department of Medicine, Center for Human Nutrition, Washington University School of Medicine, St. Louis, MO, USA.
Department of Nutrition, University of North Carolina, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Int J Diabetol Vasc Dis Res. 2015;2015(Suppl 4). doi: 10.19070/2328-353X-SI04001. Epub 2015 Sep 28.
Nearly 35% of adults and 20% of children in the United States are obese, defined as having a body mass index (BMI) ≥ 30 kg/m. Obesity is an established risk factor for many cancers, and obesity-associated metabolic perturbations often manifest in Type 2 diabetes mellitus and/or the metabolic syndrome. As part of the growth-promoting, proinflammatory microenvironment of the obese and/or diabetic state, crosstalk between macrophages, adipocytes, and epithelial cells occurs via metabolically-regulated hormones, cytokines, and other mediators to enhance cancer risk and/or progression. This review synthesizes the evidence on key biological mechanisms underlying the associations between obesity, diabetes and cancer, with particular emphasis on enhancements in growth factor signaling, inflammation, and vascular integrity processes. These interrelated pathways represent mechanistic targets for disrupting the obesity-diabetes-cancer link, and several diabetes drugs, such as metformin and rosiglitazone, are being intensely studied for repurposing as cancer chemopreventive agents.
在美国,近35%的成年人和20%的儿童患有肥胖症,定义为体重指数(BMI)≥30kg/m²。肥胖是许多癌症的既定风险因素,肥胖相关的代谢紊乱通常表现为2型糖尿病和/或代谢综合征。作为肥胖和/或糖尿病状态下促进生长、促炎的微环境的一部分,巨噬细胞、脂肪细胞和上皮细胞之间通过代谢调节的激素、细胞因子和其他介质发生相互作用,以增加癌症风险和/或促进癌症进展。本综述综合了关于肥胖、糖尿病和癌症之间关联的关键生物学机制的证据,特别强调生长因子信号传导、炎症和血管完整性过程的增强。这些相互关联的途径代表了破坏肥胖-糖尿病-癌症联系的机制靶点,并且几种糖尿病药物,如二甲双胍和罗格列酮,正在被深入研究以重新用作癌症化学预防剂。